Purple Biotech (PPBT) Current Assets (2014 - 2026)
Purple Biotech (PPBT) posted quarterly Current Assets of $6.8 million for Q1 2026, down 9.79% year-over-year from $7.5 million in Q1 2025, and down 31.29% quarter-over-quarter from $9.9 million in Q4 2025.
Purple Biotech (PPBT) Current Assets (2014 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Current Assets for 13 consecutive years, with $6.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets fell 9.79% year-over-year to $6.8 million; the TTM figure through Mar 2026 stood at $6.8 million (down 9.79% YoY), while the FY2025 annual figure was $9.9 million, up 10.75% from the prior year.
- Current Assets eased to $6.8 million in Q1 2026 per PPBT's latest filing, from $9.9 million in the prior quarter.
- Across five years, Current Assets topped out at $41.9 million in Q1 2022 and bottomed at $6.3 million in Q2 2025.
- Historically, Current Assets has averaged $17.6 million across 5 years, with a median of $11.4 million in 2024.
- Annual changes were most pronounced in 2024 — Current Assets sank 59.43% — and 2025, when it jumped 55.29%.
- Purple Biotech's Current Assets stood at $33.3 million in 2022, then tumbled by 52.53% to $15.8 million in 2023, then tumbled by 43.58% to $8.9 million in 2024, then advanced by 10.75% to $9.9 million in 2025, then slumped by 31.29% to $6.8 million in 2026.
- Business Quant data shows PPBT's Current Assets at $6.8 million in Q1 2026, $9.9 million in Q4 2025, and $10.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.61 Bn | 131.75 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.28 Bn | 60.09 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 59.14 Bn | 54.00 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.83 Bn | 28.52 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 1.76 Bn |
| 10 | Purple Biotech | 127.07 | 127.07 | - | 6.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.78 Mn |
| Dec 31, 2025 | 9.87 Mn |
| Sep 30, 2025 | 10.77 Mn |
| Jun 30, 2025 | 6.31 Mn |
| Mar 31, 2025 | 7.52 Mn |
| Dec 31, 2024 | 8.91 Mn |
| Sep 30, 2024 | 6.94 Mn |
| Jun 30, 2024 | 7.86 Mn |
| Mar 31, 2024 | 11.40 Mn |
| Dec 31, 2023 | 15.79 Mn |
| Sep 30, 2023 | 16.72 Mn |
| Jun 30, 2023 | 19.38 Mn |
| Mar 31, 2023 | 24.41 Mn |
| Dec 31, 2022 | 33.26 Mn |
| Sep 30, 2022 | 34.31 Mn |
| Jun 30, 2022 | 37.45 Mn |
| Mar 31, 2022 | 41.90 Mn |
| Dec 31, 2021 | 48.47 Mn |
| Sep 30, 2021 | 47.20 Mn |
| Jun 30, 2021 | 50.00 Mn |